Veterinary Practice Acquisition UK: 2026 Guide

The UK veterinary sector is worth over £6.7 billion and has undergone a decade of rapid consolidation. Between 2013 and 2023, corporate ownership of UK practices rose from roughly 10% to almost 60%, driven by private equity-backed roll-up strategies across the so-called "Big 6" groups. If you own a veterinary practice and have been watching this market shift, 2026 brings a genuinely different landscape to navigate.

The Competition and Markets Authority published its final market investigation report on 24 March 2026, introducing legally binding reforms that will reshape how practices are valued, marketed, and acquired. The Big 6 consolidators are constrained. New buyers have entered the market. And the BADR tax rate rises from 14% to 18% on 6 April 2026, adding urgency for owners approaching an exit.

This guide covers how veterinary practices are valued in 2026, who is buying, what the CMA reforms mean for your sale, and the practical steps to prepare your practice for a premium outcome.

How Veterinary Practices Are Valued in 2026

EBITDA multiples remain the dominant valuation methodology for veterinary practice transactions. Corporate and PE-backed buyers use adjusted EBITDA - your practice's earnings before interest, taxes, depreciation, and amortisation, normalised for owner compensation and one-off costs - as the baseline for their offers.

The critical adjustment is owner compensation. If you pay yourself £150,000 but a locum vet doing your clinical hours would cost £85,000, the £65,000 difference gets added back to your EBITDA. Other common add-backs include personal expenses through the business, non-recurring costs, and above-market rent if you own the premises.

2026 EBITDA Multiple Ranges

These ranges reflect the current market. Multiples have softened slightly from peak levels in 2021-2022, when buyer competition among the Big 6 was at its most intense. The CMA's intervention - requiring divestments in several high-profile deals - introduced execution risk that cooled the market. However, according to Eclipse Corporate Finance's 2026 market analysis, consolidation continues at a steadier pace with greater emphasis on operational quality over financial engineering.

What Drives Your Multiple Higher

Several factors push a practice toward the upper end of the range:

• Recurring revenue from care plans: Practices with structured wellness plans (similar to CVS Group's Healthy Pet Club, which has over 507,000 members) demonstrate predictable income that buyers value highly
• Multi-vet coverage: If the practice operates without the principal being present every day, the risk premium drops significantly. Buyers pay 1-2 additional turns for genuine owner independence
• Geographic positioning: Practices in areas with limited corporate presence command premiums, particularly as CMA scrutiny makes overlapping acquisitions harder
• Specialist capabilities: Referral-quality equipment, advanced diagnostics, or certified specialist vets push multiples into double digits
• Strong associate retention: With ongoing workforce pressures across the profession, a stable clinical team is a significant asset. The same principle applies across healthcare M&A - our analysis of medispa clinic valuations shows that practitioner retention is consistently one of the top value drivers

Preparing Your Practice for Sale

The gap between a 5x and a 7x multiple on a practice generating £250,000 in adjusted EBITDA is £500,000 in enterprise value. Preparation is where that gap gets closed.

Financial clean-up (3-6 months before marketing)

Strip out personal expenses. Normalise owner compensation. Ensure your management accounts are accurate and up to date. Buyers and their accountants will scrutinise every line, and unexplained costs or inconsistencies slow deals down and erode trust.

If you own the practice premises separately, get an independent rent review. Above-market rent suppresses EBITDA artificially, while below-market rent inflates it - and buyers will adjust regardless. Setting a fair market rent before going to market avoids a contentious negotiation.

Operational improvements (6-12 months before marketing)

• Reduce clinical dependency on you: Transition key client relationships to associates. If every complex case defaults to the principal, the business is you - and that limits what a buyer will pay
• Implement or upgrade practice management software: Buyers expect clean data on revenue per vet, average transaction values, new client acquisition rates, and care plan penetration. If your PMS cannot produce these reports, invest in one that can
• Stabilise staffing: Recruit and retain associates. Vet nurse recruitment has improved - the RCVS workforce model projects supply exceeding demand by 2025-2026 - but experienced associate vets remain scarce. Lock in your team with competitive packages before going to market
• Build recurring revenue: Wellness plans, vaccination reminders, and preventive care packages smooth revenue and demonstrate predictability. A practice with 30%+ recurring revenue is far more attractive than one reliant on walk-in emergencies

Regulatory and compliance readiness

The CMA's reforms mean every practice will soon need to publish standard price lists, provide written estimates for treatments over £500, and clearly disclose ownership structure. Getting ahead of these requirements signals to buyers that the practice is well-managed and low-risk.

Ensure your RCVS Practice Standards Scheme accreditation is current. Core Standards is the minimum, but practices with Awards in areas like Team & Professional Responsibility or Client Service demonstrate higher operational maturity.

The Buyer Landscape in 2026: Who Is Acquiring Practices

The buyer landscape has shifted materially. Understanding who is actively acquiring - and what they prioritise - is essential to positioning your practice correctly.

The Big 6: Still Present but Constrained

The six largest veterinary groups in the UK are CVS Group, IVC Evidensia, Linnaeus (owned by Mars), VetPartners, Medivet, and Pets at Home (operating as Vets for Pets). Together they own over 60% of UK practices.

Following the CMA's final report, these groups face heightened merger scrutiny. The regulator has stated it will "continue to actively monitor merger activity in the veterinary sector for any relevant acquisitions that may harm competition." In practical terms, this means the Big 6 are more selective, targeting practices in geographic areas where they have no existing presence and avoiding deals that would push their local market share above the CMA's 30% full-time-equivalent vet threshold.

CVS Group reported FY2025 revenue of £673.2 million (up 5.4%) and adjusted EBITDA of £134.6 million. These are well-capitalised businesses with acquisition budgets, but CMA constraints mean they cannot buy as freely as they once did.

Emerging Platforms: The New Active Buyers

Two newer platforms have stepped into the gap left by the Big 6's reduced activity, and practice owners exploring their options should look at how buy-side interest is developing across our sectors:

• Kin Vet Community (backed by Perwyn): Built a 20+ site platform since 2023 through steady bolt-on acquisitions. Focused on clinician-led culture and operational quality
• VetThing (UK arm of Vetopia, backed by Axcel): Entered the UK market in late 2025 with a differentiated ownership model and active expansion strategy

These platforms operate below the CMA's radar and can move faster on acquisitions without the regulatory overhang that affects larger groups.

Individual and Small Group Buyers

For solo practices with EBITDA under £150,000, the most likely buyer remains an individual vet or small partnership. These transactions typically complete at 3-5x EBITDA, with simpler deal structures and shorter timelines. The trade-off is a lower multiple, but often greater flexibility on transition terms and practice culture.

The CMA Reforms: What They Mean for Your Sale

The CMA's final report on veterinary services, published 24 March 2026, introduces legally binding remedies that will take effect from September 2026 onwards. While these reforms are primarily consumer-facing, they have direct implications for practice valuations and deal structures.

Key reforms

• Mandatory price transparency: All practices must publish standard price lists for common treatments and provide written estimates for any treatment expected to cost £500 or more
• Prescription fee caps: Written prescription fees capped at £21 for the first medicine and £12.50 for each additional. This limits a revenue line that some corporate groups had inflated post-acquisition
• Ownership disclosure: Practices that are part of larger groups must clearly display this on signage, premises, and online communications
• RCVS oversight: The RCVS takes a central monitoring role, funded by a new levy of approximately £450-£550 per practice annually
• Clinician empowerment: Businesses must have written policies ensuring vets can offer independent and impartial advice, free from commercial pressure

Impact on valuations

Practices that already operate transparently and charge fair prices will see minimal impact. The reforms primarily squeeze margins at practices where post-acquisition price increases were a core part of the value creation thesis. For independent practice owners selling into this environment, the key implication is that buyers can no longer rely on opaque price increases to justify premium multiples.

This is actually positive for well-run independent practices. Buyers are now forced to compete on operational quality, efficiency, and genuine growth - exactly the areas where prepared sellers can demonstrate value.

Timing

If you are considering a sale, completing before the full regulatory regime takes effect means your buyer has a clearer runway to integrate without immediate compliance costs. Equally, buyers may factor those costs into their offers for deals completing in late 2026 or 2027.

The Sale Process: Timeline and What to Expect

A typical veterinary practice sale in the UK follows a structured process. The timeline depends on practice size, buyer type, and deal complexity, but you should plan for 4-8 months from engaging an adviser to completion.

Stage-by-stage timeline

BADR tax considerations

The BADR rate increases from 14% to 18% on 6 April 2026. If you have not already exchanged contracts, completing before this deadline is no longer possible. However, BADR at 18% still saves £60,000 on a £1 million qualifying gain compared to the standard 24% CGT rate. The relief has not been abolished - the rate has increased.

For practice owners with gains above the £1 million BADR lifetime limit, structuring considerations (earn-outs, deferred consideration) become important. Similar exit planning dynamics apply across our healthcare sectors - see our guide to selling a dental practice for how the process works in adjacent healthcare niches. These are specialist areas where your M&A adviser and tax accountant need to work closely together.

Earn-out structures

Most corporate and PE-backed buyers now include an earn-out component, particularly for practices where the principal's clinical involvement is significant. A typical structure might be 70-80% cash at completion with 20-30% contingent on the practice meeting revenue or EBITDA targets over 1-3 years. You should expect to remain clinically involved for 1-3 years post-completion, with some buyers requesting up to 5 years.

Frequently Asked Questions

What is my veterinary practice worth in 2026?

Most UK veterinary practices sell for between 4x and 8x adjusted EBITDA. The exact multiple depends on practice size, number of vets, recurring revenue mix, geographic location, and buyer type. A multi-vet practice generating £250,000 in adjusted EBITDA might sell for £1.25 million to £2 million depending on these factors.

How has the CMA investigation affected veterinary practice values?

The CMA's final report (March 2026) introduced transparency and pricing reforms but stopped short of structural remedies like ownership caps. Valuations have moderated from 2021-2022 peaks but remain strong for quality practices. The main effect has been to slow acquisition activity among the Big 6 and shift deals toward smaller, emerging platforms.

Who are the main buyers of UK veterinary practices in 2026?

The Big 6 (CVS, IVC Evidensia, Linnaeus, VetPartners, Medivet, Pets at Home) remain active but are more selective due to CMA scrutiny. Emerging platforms like Kin Vet Community (Perwyn-backed) and VetThing (Axcel-backed) are the most active new acquirers. Individual vets and small groups continue to buy smaller, single-site practices.

How long does it take to sell a veterinary practice?

Plan for 4-8 months from engaging an adviser to completion. Simpler single-site sales to individual buyers can complete faster (3-4 months). Multi-site group transactions or deals involving CMA review can take 6-12 months.

Do I have to stay on after selling my practice?

Almost always, yes. Buyers typically require the selling principal to remain clinically involved for 1-3 years post-completion. For PE-backed buyers, 3-5 year retention periods are common, often linked to earn-out payments. The transition plan is a key deal term - negotiate it carefully.

What does the CMA's price transparency requirement mean for my practice?

From late 2026, all practices must publish standard price lists and provide written estimates for treatments over £500. Practices that already charge fairly and communicate transparently will see minimal impact. The reform primarily affects practices that relied on opaque pricing to inflate margins after corporate acquisition.

Should I sell before the CMA remedies take effect?

Not necessarily. The remedies do not reduce practice values for well-run businesses. However, buyers may factor compliance costs (including the new RCVS levy of £450-£550 per practice annually) into their valuations for deals completing in late 2026 or 2027. Selling earlier in 2026 removes this uncertainty.

What is the difference between selling to a corporate and an individual vet?

Corporate buyers typically pay higher multiples (6-10x EBITDA) but require longer retention periods, more complex deal structures, and may change the practice's culture post-completion. Individual buyers pay lower multiples (3-5x) but offer simpler transactions, faster completion, and often better cultural continuity.

How do I maximise my practice's value before selling?

Focus on three areas: reduce your clinical involvement so the practice operates independently, build recurring revenue through wellness plans and preventive care packages, and ensure your financials are clean with normalised owner compensation. These actions typically add 1-2 turns to your multiple - worth £250,000-£500,000 on a practice generating £250,000 EBITDA.

Can I sell if I own the practice premises?

Yes. You can sell the business and retain the property (common for practices with valuable freehold sites), sell both together, or establish a formal lease arrangement. Most corporate buyers prefer to lease rather than buy property. The rent arrangement directly affects your EBITDA, so structuring this correctly is important for maximising your total proceeds.

Take the Next Step

The veterinary M&A market in 2026 is more nuanced than at any point in the past decade. The Big 6 are constrained, new buyers have entered, the CMA has reshaped the regulatory environment, and the BADR tax rate has increased. These changes create both challenges and opportunities for practice owners considering a sale.

The owners who achieve the strongest outcomes are those who prepare early, understand their buyer options, and enter the process with clean financials, a stable team, and a clear transition plan. Whether your exit is 6 months away or 2-3 years out, the preparation you begin now directly determines the multiple you achieve.

Contact DealFlowAgent for a confidential, no-obligation conversation about your practice, the current buyer landscape, and what your exit could realistically look like. We work with veterinary and healthcare practice owners across the UK, connecting them with the right acquirers at the right time.

Your Advisory Team

Experienced Dealmakers Lead Your Exit

Every exit is led by a senior advisor who has been through it themselves. Meet the team who will guide you.

Joe Lewin

Founder & Lead Advisor

• •Built and sold first company after scaling to 80,000 users in 18 months
• •Raised £2m+ funding, built 12,000+ buyer network
• •Worked on 20+ transactions, spoken to hundreds of acquirers
• •Full-stack developer, building AI agents and SaaS platforms

Joe Thomason

Senior M&A Advisor

• •Previously Analyst at KBS Corporate
• •Analyst at Hampleton Partners, Associate at Tech Credit Partners
• •Worked on 25+ completed transactions (£300k to £120m)
• •Specialist in debt lending for business buyers

Emerson Patton

Sector Specialist: Building, Construction & Trade Services

• •20+ years advising owners in building services, fire safety, HVAC, plumbing, and construction
• •Guided 200+ companies through growth, profit improvement, and exit planning
• •Builds equity value and operational structure long before a sale
• •Partners with DFA to prepare owners for exit while the advisory team runs the sale

Sam Pouyan

Senior M&A Advisor

• •10 years across buy-side and sell-side M&A
• •Former investment banking analyst
• •Expert in financial modelling and deal structuring

Sage

AI Deal Concierge

• •Available 24/7. Monitors every signal in your deal
• •Keeps your advisory team one step ahead at all times
• •Trained on thousands of M&A transactions

Tim Armoo

Partner & Chief Marketing Officer

• •Founded Fanbytes, scaled revenues to £10m+, exited at multi-eight-figure valuation
• •Advises on multiple M&A deals, invests in early-stage ventures
• •Built 700,000+ follower community teaching founders to scale and sell
• •Partnered with DealFlowAgent to expand access for founders to buyers

Assigned Per Deal

Sector Expert

Industry-Specific M&A Advisor

For every deal, our advisory team includes a sector specialist from that client's specific industry and niche: bringing relationships, insider knowledge, and leverage to support your process and achieve the best acquisition outcome.

Healthcare M&A Specialists

Thinking of selling your healthcare business?

DealFlowAgent is the UK and US's only M&A advisory firm specialising in healthcare businesses. Our trusted advisors leverage industry knowledge, buyer relationships and proprietary technology to help business owners secure multiple acquisition offers at higher valuations.

Talk to a Real Advisor - No Obligation

Speak with Joe or Sam about your situation. No hard sell, no commitment, just honest advice from advisors who've been through it.

What's Your Business Actually Worth?

Our valuation tool gives you a realistic range based on recent comparable transactions in your sector. Takes 3 minutes.

Related Articles